CT scan could predict asthma drug success, saving months of trial and error

NCT ID NCT03976310

Completed Knowledge-focused Sponsor: University Hospital, Montpellier Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested whether a CT scan of the lungs could predict which patients with severe eosinophilic asthma would respond well to the drug benralizumab. 59 adults received benralizumab for 48 weeks and had CT scans at the start, middle, and end of treatment. The goal was to see if air-trapping patterns on the initial scan could forecast a significant reduction in asthma attacks after one year, potentially helping doctors choose the right treatment faster.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Benralizumab
What this could lead to: If successful, this could help doctors quickly identify which asthma patients are most likely to benefit from benralizumab, avoiding months of ineffective treatment.
What could go wrong: This is a small, completed study (59 people) that looked at predicting response, not testing the drug itself. The findings may not apply to all patients or guarantee better outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ASTHMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

asthma T2-high asthma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ASTHMA

Contacts and locations

Locations

Assistance Publique - Hopitaux de Marseille

Marseille, 13915, France
University Hospitals of Montpellier

Montpellier, 34295, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.